Enlivex Therapeutics (NASDAQ:ENLV) Upgraded at Zacks Research

Zacks Research upgraded shares of Enlivex Therapeutics (NASDAQ:ENLV) from a hold rating to a strong-buy rating in a report issued on Tuesday morning,Zacks.com reports.

Several other research analysts have also issued reports on the stock. Wall Street Zen upgraded shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 25th. Weiss Ratings reissued a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. Finally, HC Wainwright boosted their target price on shares of Enlivex Therapeutics from $195.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $247.50.

Enlivex Therapeutics Price Performance

Shares of ENLV opened at $4.36 on Tuesday. The business has a 50-day moving average of $8.98 and a 200-day moving average of $12.80. The company has a market capitalization of $73.38 million, a price-to-earnings ratio of -0.53 and a beta of 1.52. Enlivex Therapeutics has a 1 year low of $4.25 and a 1 year high of $31.50.

Institutional Trading of Enlivex Therapeutics

Hedge funds have recently bought and sold shares of the business. Virtu Financial LLC acquired a new position in Enlivex Therapeutics during the fourth quarter worth $33,000. Susquehanna International Group LLP bought a new position in shares of Enlivex Therapeutics in the third quarter valued at approximately $57,000. Invesco Ltd. purchased a new position in shares of Enlivex Therapeutics during the fourth quarter valued at approximately $43,000. XTX Topco Ltd boosted its position in shares of Enlivex Therapeutics by 44.8% during the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after buying an additional 19,132 shares during the last quarter. Finally, Jane Street Group LLC grew its holdings in Enlivex Therapeutics by 244.1% during the fourth quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock worth $52,000 after buying an additional 52,553 shares in the last quarter. Institutional investors and hedge funds own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.